1 308

Cited 36 times in

Mirtazapine for patients with alcohol dependence and comorbid depressive disorders: A multicentre, open label study

Authors
 Su-Jung Yoon  ;  Chi-Un Pae  ;  Dai-Jin Kim  ;  Kee Namkoong  ;  Eun Lee  ;  Dong-Yul Oh  ;  Young-Sik Lee  ;  Dong-Hwan Shin  ;  Young-Cheol Jeong  ;  Joon-Hong Kim  ;  Sung-Bin Choi  ;  In-Bok Hwang  ;  Young-Chul Shin  ;  Sung-Nam Cho  ;  Hae Kook Lee  ;  Chung Tai Lee 
Citation
 PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, Vol.30(7) : 1196-1201, 2006 
Journal Title
 PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY 
ISSN
 0278-5846 
Issue Date
2006
MeSH
Adult ; Alcoholism/drug therapy* ; Alcoholism/epidemiology* ; Antidepressive Agents, Tricyclic/therapeutic use* ; Comorbidity ; Depressive Disorder/drug therapy* ; Depressive Disorder/epidemiology* ; Female ; Humans ; Male ; Mianserin/analogs & derivatives* ; Mianserin/therapeutic use ; Middle Aged ; Mirtazapine ; Outcome Assessment (Health Care) ; Pain Measurement/methods ; Severity of Illness Index ; Time Factors
Keywords
Alcohol dependence ; CravingDepressive disorder ; Mirtazapine
Abstract
Major depressive disorder and alcohol dependence are common and serious mental illnesses. There is a great interest in discovering useful treatments for both mood symptoms and alcohol abuse in those patients with depressive disorders and comorbid alcohol dependence. The primary purpose of this study was to evaluate the effectiveness and tolerability of mirtazapine for the treatment of patients with alcohol dependence comorbid with a depressive disorder in an open label, naturalistic multicentre treatment setting. The 17-item Hamilton Depression Rating Scale (HDRS), the Hamilton Anxiety Rating Scale (HARS) and the Clinical Global Impression-Severity (CGI-S) scale were measured at baseline and at weeks 4 and 8 for the assessment of treatment effectiveness. Alcohol craving was measured using the Obsessive Compulsive Drinking Scale (OCDS) and the Visual Analog Scale for Craving (VAS). This study showed a statistically significant reduction of the scores on the HDRS (13.9 ± 7.3, p < 0.0001), HARS (10.8 ± 7.2, p < 0.0001) and the CGI-S (1.7 ± 1.0, p < 0.0001) from baseline to the endpoint (week 8). The OCDS and VAS scores were also decreased significantly by 42.3% and 53.2% (9.0 ± 10.0, p < 0.0001; 2.5 ± 2.4, p < 0.0001, respectively). The number of patients with a 50% reduction or more in the HDRS and HARS scores was 103 (72.0%) and 106 (74.1%) at the endpoint, respectively. Adverse events related to mirtazapine were observed in 10% or more of the patients in this study. In conclusion, the results from this naturalistic study suggest that the use of mirtazapine for the patients with alcohol dependence comorbid with depressive disorder is accompanied by clinical improvement in their mood and alcohol craving.
Full Text
http://www.sciencedirect.com/science/article/pii/S0278584606000777
DOI
10.1016/j.pnpbp.2006.02.018
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Psychiatry (정신과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
Yonsei Authors
Namkoong, Kee(남궁기) ORCID logo https://orcid.org/0000-0003-1400-8057
Shin, Dong Hwan(신동환)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/109853
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links